$39.34
1.21% yesterday
Nasdaq, Apr 03, 10:15 pm CET
ISIN
US88322Q1085
Symbol
TGTX
Sector
Industry

TG Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation

TG Therapeutics, Inc. Classifications & Recommendation:

Buy
88%
Sell
13%

TG Therapeutics, Inc. Price Target

Target Price $43.00
Price $39.34
Potential
Number of Estimates 6
6 Analysts have issued a price target TG Therapeutics, Inc. 2026 . The average TG Therapeutics, Inc. target price is $43.00. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 8 analysts: 7 Analysts recommend TG Therapeutics, Inc. to buy, 0 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the TG Therapeutics, Inc. stock has an average upside potential 2026 of . Most analysts recommend the TG Therapeutics, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 329.00 553.43
40.80% 68.22%
EBITDA Margin 12.83% 35.78%
42.35% 178.88%
Net Margin 7.11% 27.27%
18.37% 283.81%

6 Analysts have issued a sales forecast TG Therapeutics, Inc. 2025 . The average TG Therapeutics, Inc. sales estimate is

$553m
Unlock
. This is
68.22% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$595m 80.85%
Unlock
, the lowest is
$540m 64.10%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $329m 40.80%
2025
$553m 68.22%
Unlock
2026
$783m 41.43%
Unlock
2027
$967m 23.56%
Unlock
2028
$1.3b 29.35%
Unlock
2029
$1.6b 27.03%
Unlock

2 Analysts have issued an TG Therapeutics, Inc. EBITDA forecast 2025. The average TG Therapeutics, Inc. EBITDA estimate is

$198m
Unlock
. This is
369.19% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$244m 478.27%
Unlock
, the lowest is
$152m 260.10%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $42.2m 100.43%
2025
$198m 369.19%
Unlock
2026
$317m 59.86%
Unlock
2027
$330m 4.24%
Unlock

EBITDA Margin

2024 12.83% 42.35%
2025
35.78% 178.88%
Unlock
2026
40.45% 13.05%
Unlock
2027
34.12% 15.65%
Unlock

7 TG Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average TG Therapeutics, Inc. net profit estimate is

$151m
Unlock
. This is
591.83% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$218m 900.02%
Unlock
, the lowest is
$68.6m 214.29%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $23.4m 66.67%
2025
$151m 545.70%
Unlock
2026
$300m 98.97%
Unlock
2027
$393m 30.76%
Unlock
2028
$596m 51.78%
Unlock
2029
$728m 22.09%
Unlock

Net Margin

2024 7.11% 18.37%
2025
27.27% 283.81%
Unlock
2026
38.37% 40.70%
Unlock
2027
40.61% 5.84%
Unlock
2028
47.65% 17.34%
Unlock
2029
45.80% 3.88%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ 0.15 0.97
66.67% 546.67%
P/E 40.62
EV/Sales 11.06

7 Analysts have issued a TG Therapeutics, Inc. forecast for earnings per share. The average TG Therapeutics, Inc. EPS is

$0.97
Unlock
. This is
592.86% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$1.40 900.00%
Unlock
, the lowest is
$0.44 214.29%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $0.15 66.67%
2025
$0.97 546.67%
Unlock
2026
$1.93 98.97%
Unlock
2027
$2.52 30.57%
Unlock
2028
$3.83 51.98%
Unlock
2029
$4.67 21.93%
Unlock

P/E ratio

Current 281.81 73.88%
2025
40.62 85.59%
Unlock
2026
20.41 49.75%
Unlock
2027
15.61 23.52%
Unlock
2028
10.28 34.14%
Unlock
2029
8.42 18.09%
Unlock

Based on analysts' sales estimates for 2025, the TG Therapeutics, Inc. stock is valued at an EV/Sales of

11.06
Unlock
and an P/S ratio of
11.17
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 18.61 93.85%
2025
11.06 40.56%
Unlock
2026
7.82 29.29%
Unlock
2027
6.33 19.07%
Unlock
2028
4.89 22.69%
Unlock
2029
3.85 21.28%
Unlock

P/S ratio

Current 18.78 86.85%
2025
11.17 40.55%
Unlock
2026
7.89 29.29%
Unlock
2027
6.39 19.07%
Unlock
2028
4.94 22.69%
Unlock
2029
3.89 21.28%
Unlock

Current TG Therapeutics, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Mar 04 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 15 2025
JP Morgan
Locked
Locked
Locked Nov 25 2024
Goldman Sachs
Locked
Locked
Locked Nov 05 2024
HC Wainwright & Co.
Locked
Locked
Locked Nov 05 2024
TD Cowen
Locked
Locked
Locked Oct 29 2024
HC Wainwright & Co.
Locked
Locked
Locked Sep 18 2024
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 04 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 15 2025
Locked
JP Morgan:
Locked
Locked
Nov 25 2024
Locked
Goldman Sachs:
Locked
Locked
Nov 05 2024
Locked
HC Wainwright & Co.:
Locked
Locked
Nov 05 2024
Locked
TD Cowen:
Locked
Locked
Oct 29 2024
Locked
HC Wainwright & Co.:
Locked
Locked
Sep 18 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today